EIP
SAGE

Easterly Investment Partners’s Sage Therapeutics SAGE Stock Holding History

Easterly Investment Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$206K – 203
2023
Q3 		$206K Sell
10,000
-32,800
-77% -$947K 0.02% 174
2023
Q2 		$2.01M Buy
+42,800
New +$2.13M 0.18% 109

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Easterly Investment Partners's SAGE Position: Q2 2025 in Review

Easterly Investment Partners sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 27,000 shares — an estimated $215K sold.

Easterly Investment Partners first reported a position in SAGE in Q1 2022 and held it in 13 quarters. The position peaked at $4.03M in Q3 2023. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Easterly Investment Partners reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Easterly Investment Partners sold 27,000 Sage Therapeutics shares in Q2 2025, an estimated $215K.
  • Easterly Investment Partners first reported a position in Sage Therapeutics in Q1 2022 and held it in 13 quarters.
  • Easterly Investment Partners's Sage Therapeutics position peaked at $4.03M in Q3 2023.
  • 192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Easterly Investment Partners's 13F filing for Q2 2025, filed 29 Jul 2025.